Market Overview

UPDATE: Jefferies Upgrades Shire to Buy on Entry Opportunity, Pipeline Outlook

Share:
Related
SunTrust Names Eli Lilly, Merck, Bristol-Myers as 'Favorite' Pharma Firms
Cowen On Shire: 'Add Aggressively'
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary (Zacks)

Jefferies raised its rating on Shire (NASDAQ: SHPG) from Hold to Buy and increased its price target from $100 to $117.

Jefferies commented, "We upgrade to Buy as pipeline news is warming-up and there are fewer uncertainties for the important ADHD franchise, after a challenging YTD for the stock down c.20% (-33% vs sector DRG). Robust +13% 2013-16E EPS CAGR justifies a 15% premium to peers, versus the currently depressed 10% discount and 20% haircut to its own historic forward PE. Heightened confidence in the mid-term growth trajectory should trigger a re-rating, in our view."

Shire closed at $87.27 on Wednesday.

Latest Ratings for SHPG

DateFirmActionFromTo
Mar 2015BernsteinUpgradesMarket PerformOutperform
Mar 2015Leerink SwannMaintainsMarket Perform
Feb 2015JP MorganMaintainsOverweight

View More Analyst Ratings for SHPG
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (SHPG)

Around the Web, We're Loving...